End-stage renal failure and cardiac mortality after heart transplantation

Clinical Transplantation

Volumn 18, Issue 1, 2004, Pages 1-6

  Sénéchal, Mario ^a,b   Dorent, Richard ^a   Tézénas du Montcel, Sophie ^a   Ghossoub, Jean Jacques ^a   Pavie, Alain ^a   Petitclerc, Thierry ^a   Dubois, Michelle ^a   Isnard, Richard ^a   Gandjbakhch, Iradj ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Cardiac mortality; Dialysis; Heart transplantation; Hypertriglyceridemia; Lend stage renal failure

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN A; PREDNISONE; THYMOCYTE ANTIBODY; TRIACYLGLYCEROL;

ADULT; ATHEROSCLEROSIS; CASE CONTROL STUDY; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIALYSIS; DOSE RESPONSE; FEMALE; GRAFT REJECTION; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART TRANSPLANTATION; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; STATISTICAL SIGNIFICANCE; SUDDEN DEATH; SURVIVAL; TRIACYLGLYCEROL BLOOD LEVEL; UREMIA;

ADULT; CASE-CONTROL STUDIES; CORONARY DISEASE; CYCLOSPORINE; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TRIGLYCERIDES;

EID: 1042304235     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2004.00105.x     Document Type: Review

References (34)

1. Hosenpud J, Bennett L, Berkeley M et al. The registry of the International Society for Heart and Lung Transplantation: Eighteenth Official Report-2001. J Heart Lung Transplant 2001: 20: 805.
2. Gelder T, Balk Ahmm, Zietse R, Hesse C, Mochtar B, Weimar W. Renal insufficiency after heart transplantation: a case-control study. Nephrol Dial Transplant 1998: 13: 2322.
3. Gao Z, Schroeder J, Alderman E. Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation 1987: 76 (Suppl. V): 56.
4. Bertani T, Ferrazzi P, Schieppati A, Ruggenti P, Gamba A, Parenzan L. Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney Int 1991: 40: 243.
5. Thomson SG, Tucker BJ, Gabbai F, Blantz RC. Functional effects on glomerular hemodynamics of short-term chronic cyclosporine in male rats. J Clin Invest 1989: 83: 960.
6. Zietse R, Balk Ahmm, Dorpel van den MA, Meeter K, Bos E, Weimar W. Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am J Nephrol 1994: 14: 1.
7. Esposito C, Semeraro L, Bellotti N, Fasoli G, Fornoni A, Rampino T. Risk factors for chronic renal dysfunction in cardiac allograft recipients. Nephron 2000: 84: 21.
8. Baan CC, Balk Ahmm, Holweg CTJ, Van Riemsdijk IC, Maat LPWM, Vantrimpont PJMJ. Renal failure after clinical heart transplantation is associated with the TGF-β1 Codon 10 gene polymorphism. J Heart Lung Transplant 2000: 19: 866.
9. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993: 270: 1339.
10. Rostand SG, Kirk KA, Rutsky EA. Dialysis-associated ischemic heart disease: insights from coronary angiography. Kidney Int 1984: 25: 653.
11. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974: 290: 697.
12. Rostand SG, Gretes JC, Kirk KA, Rutsky EA, Andreoli TE. Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis. Kidney Int 1979: 16: 600.
13. Gradaus F, Ivens K, Peters AJ et al. Angiographic progression of coronary artery disease in patients with endstage renal disease. Nephrol Dial Transplant 2001: 16: 1198.
14. Kuo PC, Luikart H, Busse-Henry S, Hunt SA, Valantine HA, Stinson EB. Clinical outcome of interval cadaveric renal transplantation in cardiac allograft recipients. Clin Transplant 1995: 9: 92.
15. Ballantyne CM, Radovancevic B, Farmer JA et al. Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. JACC 1992: 19: 1315.
16. Wanner C, Zimmermenn J, Quaschning T, Galle J. Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients. Kidney Int 1997: 52: S53.
17. Bologa RM, Levine DM, Parker TL et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998: 32: 107.
18. Samuelsson O, Aurell M, Knight-Gibson C, Alaupovich P, Attman PO. Apolipoprotein-B-containing lipoprotein and the progression of renal insufficiency. Nephron 1993: 63: 279.
19. Wheeler DC, Chana RS, Topley N, Petersen HM, Davies M, Williams JD. Oxidation of low density lipoproteins by mesangial cells may promote glomerular injury. Kidney Int 1994: 45: 1628.
20. Fuiano G, Esposito C, Sepe V et al. Effects of hypercholesterolemia on renal hemodynamics: study in patients with nephrotic syndrome. Nephron 1996: 73: 430.
21. Galle J, Wanner C. Impact of nitric oxide on renal hemodynamic and glomerular function: modulation by atherogenic lipoproteins? Kidney Blood Press Res 1996: 19: 2.
22. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal disease. Lancet 2001: 357: 1601.
23. Valantine H, Rickenbacker P, Kemma M et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study. Circulation 2001: 103: 2144.
24. Tchernof A, Lamarche B, Prud'Homme D et al. The dense LDL phenotype: associations with plasma lipoprotein levels, visceral obesity and hyperinsulinemia in men. Diabetes Care 1996: 19: 629.
25. Campos H, Genest JJ, Blijlevens E et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 1992: 12: 187.
26. Lamarche B, Tchernof A, Moorjani S et al. Small, dense low-density lipoprotein particle as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation 1997: 95: 69.
27. United States renal data system 1996 Annual data report. Am J Kidney Dis 1996: 28 (Suppl. 2): 95.
28. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989: 36: 286.
29. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996: 27: 347.
30. Greaves SC, Gamble GD, Collins JF, Whalley GA, Sharpe N. Determinants of left ventricular hypertrophy and systolic dyafunction in chronic renal failure. Am J Kidney Dis 1994: 24: 768.
31. Stefoni S, Cianciolo G, Konati G et al. Low TGF-β1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int 2002: 61: 324.
32. Bachmann J, Tepel M, Raidt H et al. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995: 6: 121.
33. Zimmerman J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999: 55: 648.
34. Takeda K, Harada A, Okuda S et al. Sudden death in chronic dialysis patients. Nephrol Dial Tranplant 1997: 12: 952.